DDrare: Database of Drug Development for Rare Diseases

272. 進行性骨化性線維異形成症
［臨床試験数：23，薬物数：21（DrugBank：4），標的遺伝子数：10，標的パスウェイ数：87］

Searched query = "Fibrodysplasia ossificans progressiva", "FOP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AZD0530; AZD0530 Difumarate; Garetosmab; PALOVAROTENE; PALOVAROTENE - 1.5mg; PALOVAROTENE - 10 mg; PALOVAROTENE - 1mg; PALOVAROTENE - 2 mg; PALOVAROTENE - 2.5 mg; PALOVAROTENE - 3 mg; PALOVAROTENE - 4 mg; PALOVAROTENE - 5 mg; Palovarotene; Palovarotene dose level 1; Palovarotene dose level 2; Palovarotene dose level 3; Palovarotene dose level 4; Perhexiline; REGN2477; SARACATINIB DIFUMARATE; Saracatinib

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04577820 (ClinicalTrials.gov)	November 5, 2020	30/9/2020	Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)	Evaluation of Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva	Fibrodyplasia Ossificans Progressiva (FOP);Heterotopic Ossification (HO)	Drug: garetosmab	Regeneron Pharmaceuticals	NULL	Not yet recruiting	18 Years	60 Years	All	6	Phase 3	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04577820
(ClinicalTrials.gov)

November 5, 2020

30/9/2020

Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

Evaluation of Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva

Fibrodyplasia Ossificans Progressiva (FOP);Heterotopic Ossification (HO)

Drug: garetosmab

Regeneron Pharmaceuticals

NULL

Not yet recruiting

18 Years

60 Years

All

Phase 3

NULL